MOXIFLOXACIN HYDROCHLORIDE

Post-LOE

moxifloxacin ophthalmic

Gland Pharma

ANDAOPHTHALMICSOLUTION/DROPS

Approved

Mar 2020

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

MOXIFLOXACIN HYDROCHLORIDE (moxifloxacin ophthalmic) by Gland Pharma is anti-infective drugs [see ]. Approved for bacterial conjunctivitis caused by susceptible strains of the following organisms: corynebacterium species*, micrococcus luteus*, staphylococcus aureus and 10 more indications. First approved in 2020.

Drug data last refreshed 22h ago

Mechanism of Action

anti-infective drugs [see ].

Indications (13)

bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species*Micrococcus luteus*

Worked on MOXIFLOXACIN HYDROCHLORIDE at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (2)

NCT05413980N/ACompleted

Effectiveness and Safety of 0.5% Moxifloxacin Hydrochloride Ophthalmic Solution in Perioperative Sterilization in Patients Undergoing Ophthalmic Surgery

Started Jan 2024

102 enrolled

Post Operative Endophthalmitis

NCT01573910Phase 3Completed

An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients

Started May 2012

985 enrolled

Bacterial Conjunctivitis